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TRANSLATIONAL IMMUNOLOGY IN KIDNEY DISEASE, ISN NEXUS SYMPOSIUM 2016Aim: Primary: To study the incidence and mortality of CMV
disease (CMVD) in patients receivingno induction, before and after
universal prophylaxis.
Secondary: To study the clinical proﬁle of Early Versus Late
CMVD
Methods: Retrospective observational study. CMVD diagnosed
based on CMV DNA PCR/tissue histopathology in combination with
typical signs and symptoms.
Exclusion criteria: Age <18 years and patients who received
biologic agents as induction or in post-transplant period.
Study period: September 2013 – August 2015. All were ABO
compatible live renal transplant (RTx).
For analysis of Primary outcome, patients who received no in-
duction were divided into two groups: (I) All patients transplanted
after September 2014 received oral valganciclovir at a dose of
450mg O.D. for 100 days (UNIVERSAL PROPHYLAXIS GROUP)
(II) Patients transplanted before September 2014 received no
CMV chemoprophylaxis if they had not received induction with a
biologic agent.
All patients diagnosed with post RTx CMVD from September
2013 to August 2015 were included and divided into two groups for
analysis of Secondary outcome (A) Late CMV disease (>1yr post
RTx) (B) Early CMV disease (<1yr post RTx).
Results: 28 patients were included in the study (No induction
group). All had D+ / R+ CMV serology status pretransplant. Out of
12 patients in group (II), 5 developed CMVD (41.6%). 4 out of 5
patients with CMVD had expired (80%). Out of 16 patients in group
(I), no cases of CMVD were diagnosed and 1 patient out of 16 died
due to gram negative sepsis at the end of study period. A total of 8
patients were diagnosed with CMVD during the study period and
were included for secondary outcome analysis. 5 belonged to group
A and 3 to group B. The clinical proﬁle and outcomes are repre-
sented in Table 1.
Table 1.
Early CMVD Late CMVDS4No. of patients 5 3Immunosuppression TAC/MMF/Steroids CSA/AZA/SteroidsMean duration to
develop CMVD72 days post-transplant 8 yearsDisease
ManifestationsLeucopenia and opportunistic
infections (Disseminated
Strongyloidiasis and Nocardiosis)Tissue invasive disease
(CMV hepatitis, Gastritis
and retinitis)Mean CNI Levels Tac trough levels10.3ng/ml C2 levels 708mmol/LMean CMV copies 70,000 IU/ml 1054 IU/mlOutcomes 4/5 (80%) expired Responded well to
antivirals with good
patient outcomeConclusions: Incidence of CMVD was 41.6% with a high mortal-
ity(80%) in patients without universal CMV prophylaxis. Pro-
phylaxis with oral valganciclovir irrespective of induction/no
induction should be universalized to improve patient outcomes.
Early CMVD had a high incidence of life threatening opportunistic
infections resulting in poor patient outcomes versus patients with
late CMVD who had milder non-leucopenic tissue invasive CMVD
with better outcomes.
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Introduction: Chronic kidney disease (CKD) is one major medical
condition worldwide, which leads to signiﬁcant morbidity and
mortality. CKD patients have a signiﬁcant alteration in innate and
adaptive immune responses. Disturbance in innate immune re-
sponses in CKD patients has for example been represented by
dysfunction of neutrophil granulocytes as a consequence of chronic
activation leading to high levels of inﬂammatory cytokine. Given
the vital role of basophil cells in the pathogenesis of CKD; we aimed
to study the potential inﬂammatory response of basophils in
chronic kidney disease patients on hemodialysis.
Methods: The hemodialysis patients were recruited from the
Department of Nephrology at the Karolinska University Hospital in
Stockholm, Sweden. The estimated Glomerular Filtration Rate for
the patients was (eGFR) of <20 ml/min/1.73 m2 with a residual GFR
from 6-11. Patients were undergoing hemodialysis with polysulfone
high ﬂux dialyzers, three times per week for four to four and a half
hours per dialysis before the study (n¼10). Peripheral blood sam-
ples were drawn from patients before start of hemodialysis session.
The basophil surface expression of different activation markers
CD203c (basophil selection marker), CD63 (degranulation marker),
CD11b, active CD11b, CD62L (adhesive markers) and CD300a
(inhibitory marker of degranulation) were investigated, after
stimulation of different activation pathways in basophils with
Lipopolysaccharide (LPS), peptidoglycan (PGN), formyl-methyi-
noyl-leucyl-phenylalanine (fMLP), and anti- Fc RI antibody.
Results: The basophil expression of CD63 following activation by
fMLP was signiﬁcantly higher in the patient group compared to
healthy controls, but no differences were noted after activation by
anti-FcÉiRI-ab. CD300a expression was signiﬁcantly higher in pa-
tients following activation by fMLP and anti-FcÉiRI and the active
epitope CD11b expression was signiﬁcantly higher in patients after
LPS activation. In addition, we found that CD62L, in contrast with
that in neutrophils, was not shed from basophil surface after acti-
vation with LPS and fMLP but a signiﬁcant downregulation was
observed after activation with anti-FcÉiRI-ab in healthy controls.
Conclusions: In conclusion, these data show that basophil func-
tions related to adhesion and degranulation are altered in CKD
patients which indicate a potential role for the basophil in the
pathogenesis of CKD.
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Introduction: Persistent viral hepatitis C (HCV) is the main reason
for chronic liver diseases in patients on hemodialysis (HD). The ﬂow
of infectious process in this patients’ category has important dis-
tinctions. With chronic infections, the virus has a true mutagenic
effect.
The object of the present research was to study the level of
mutation variability in peripheral blood lymphocytes of patientsKidney International Reports (2016) 1, S1–S22
